L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis

Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. C2C12 cells were differentiate...

Full description

Saved in:
Bibliographic Details
Published inNutrition & metabolism Vol. 18; no. 1; p. 98
Main Authors Wu, Changpeng, Zhu, Mingxing, Lu, Zongliang, Zhang, Yaowen, Li, Long, Li, Na, Yin, Liangyu, Wang, He, Song, Wei, Xu, Hongxia
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 01.11.2021
BioMed Central
BMC
Subjects
AKT
AKT protein
Antibodies
Atrophy
blood serum
C2C12 cells
Cachexia
Cancer
Cancer cachexia
Care and treatment
Carnitine
Cell differentiation
Colon-26
Complications and side effects
Cytokines
FOXO3 protein
Gastrocnemius muscle
Health aspects
horses
inflammation
Interleukin 1
Interleukin 6
L-Carnitine
Laboratory animals
Levocarnitine
mice
Muscle atrophy
muscles
muscular atrophy
Musculoskeletal system
Myotubes
non-specific serine/threonine protein kinase
nutrition
Protein biosynthesis
Protein kinases
Proteins
Serum levels
siRNA
Skeletal muscle
Stem cells
Transcription factors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Tumors
Ubiquitination
Wasting syndrome
Western blotting
China
United States > US
Online AccessGet full text
ISSN1743-7075
1743-7075
DOI10.1186/s12986-021-00623-7

Cover

Abstract Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-[alpha] to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-[alpha], and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured. L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-[alpha]. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-[alpha], another inducer of cachexia, in the in vivo model. These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.
AbstractList BACKGROUND: Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. METHODS: C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-α to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-α, and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured. RESULTS: L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-α. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-α, another inducer of cachexia, in the in vivo model. CONCLUSION: These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.
Background Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. Methods C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-[alpha] to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-[alpha], and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured. Results L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-[alpha]. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-[alpha], another inducer of cachexia, in the in vivo model. Conclusion These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia. Keywords: Cancer cachexia, Muscle atrophy, L-carnitine, Colon-26, C2C12 cells, AKT, p70S6K, FOXO3a
Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-[alpha] to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-[alpha], and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured. L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-[alpha]. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-[alpha], another inducer of cachexia, in the in vivo model. These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.
Abstract Background Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia. Methods C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-α to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-α, and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured. Results L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-α. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-α, another inducer of cachexia, in the in vivo model. Conclusion These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.
Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia.BACKGROUNDRecent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits remain unknown. This study was conducted to determine the mechanism by which L-carnitine reduces cancer cachexia.C2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-α to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-α, and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured.METHODSC2C12 cells were differentiated into myotubes by growing them in DMEM for 24 h (hrs) and then changing the media to DMEM supplemented with 2% horse serum. Differentiated myotubes were treated for 2 h with TNF-α to establish a muscle atrophy cell model. After treated with L-carnitine, protein expression of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K was determined by Western blotting. Then siRNA-Akt was used to determine that L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx. In vivo, the cancer cachexia model was established by subcutaneously transplanting CT26 cells into the left flanks of the BALB/c nude mice. After treated with L-carnitine, serum levels of IL-1, IL-6 and TNF-α, and the skeletal muscle content of MuRF1, MaFbx, FOXO3, p-FOXO3a, Akt, p-Akt, p70S6K and p-p70S6K were measured.L-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-α. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-α, another inducer of cachexia, in the in vivo model.RESULTSL-carnitine increased the gastrocnemius muscle (GM) weight in the CT26-bearing cachexia mouse model and the cross-sectional fiber area of the GM and myotube diameters of C2C12 cells treated with TNF-α. Additionally, L-carnitine reduced the protein expression of MuRF1, MaFbx and FOXO3a, and increased the p-FOXO3a level in vivo and in vitro. Inhibition of Akt, upstream of FOXO3a, reversed the effects of L-carnitine on the FOXO3a/MaFbx pathway and myotube diameters, without affecting FOXO3a/MuRF-1. In addition to regulating the ubiquitination of muscle proteins, L-carnitine also increased the levels of p-p70S6K and p70S6K, which are involved in protein synthesis. Akt inhibition did not reverse the effects of L-carnitine on p70S6K and p-p70S6K. Hence, L-carnitine ameliorated cancer cachexia via the Akt/FOXO3/MaFbx and p70S6K pathways. Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia. However, there were minimal effects on TNF-α, another inducer of cachexia, in the in vivo model.These results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.CONCLUSIONThese results revealed a novel mechanism by which L-carnitine protects muscle cells and reduces inflammation related to cancer cachexia.
ArticleNumber 98
Audience Academic
Author Wang, He
Zhu, Mingxing
Wu, Changpeng
Li, Na
Zhang, Yaowen
Li, Long
Lu, Zongliang
Song, Wei
Yin, Liangyu
Xu, Hongxia
Author_xml – sequence: 1
  givenname: Changpeng
  surname: Wu
  fullname: Wu, Changpeng
– sequence: 2
  givenname: Mingxing
  surname: Zhu
  fullname: Zhu, Mingxing
– sequence: 3
  givenname: Zongliang
  surname: Lu
  fullname: Lu, Zongliang
– sequence: 4
  givenname: Yaowen
  surname: Zhang
  fullname: Zhang, Yaowen
– sequence: 5
  givenname: Long
  surname: Li
  fullname: Li, Long
– sequence: 6
  givenname: Na
  surname: Li
  fullname: Li, Na
– sequence: 7
  givenname: Liangyu
  surname: Yin
  fullname: Yin, Liangyu
– sequence: 8
  givenname: He
  surname: Wang
  fullname: Wang, He
– sequence: 9
  givenname: Wei
  surname: Song
  fullname: Song, Wei
– sequence: 10
  givenname: Hongxia
  orcidid: 0000-0001-5215-734X
  surname: Xu
  fullname: Xu, Hongxia
BookMark eNqFkkuP0zAUhSM0iHnAH2AViQ0sMvXbzgapGlGoGFQJumBn3ThO6iqJBzsZyr_HbUdARwjkhS37O8f3Xp3L7Gzwg82ylxhdY6zELGJSKlEggguEBKGFfJJdYMnSAUl-9sf5PLuMcYsQpaxEz7JzyiRhpUQXmb4tDITBjW6wOfS2cz7AaGM-bmzeT9F0Nv8OMT23uW9yA4OxIW1mY3cOEhX81G4O9PzjerZYfV1RmH2CRbXLYefi8-xpA120Lx72q2y9eLe--VDcrt4vb-bpd4HkWFS0IYohqE2lJDOWGtFQ0dS14LYxlBNOLG6oNYJKVkEJgmJbgqmZqFRD6VW2PNrWHrb6Lrgewg_twenDhQ-thjC61I0mdSmswhYUrxlIXCEpBcGKK1Ezwk3yenv0upuq3tbGDmOA7sT09GVwG936e604LxlmyeD1g0Hw3yYbR927aGzXwWD9FDURVKT5M6T-j_KSUCSZ4Al99Qjd-ikMaah7qkxmiNHfVAupVzc0PpVo9qZ6LhQWPEVmX-H1X6i0ats7k1LWuHR_InhzIkjMaHdjC1OMevnl8ylLjqwJPsZgm1-jw0jvg6uPwdUpuPoQXC2TSD0SGTfC6Px-xK77l_Qnv9DvtA
CitedBy_id crossref_primary_10_1155_2023_9328344
crossref_primary_10_3390_cells12242787
crossref_primary_10_3390_ph16111580
crossref_primary_10_1186_s12967_025_06341_5
crossref_primary_10_1016_j_nut_2025_112697
crossref_primary_10_3390_nu17061010
crossref_primary_10_1186_s40360_024_00820_z
crossref_primary_10_1038_s41571_023_00734_5
crossref_primary_10_1002_mnfr_202300033
crossref_primary_10_1007_s11011_024_01475_9
crossref_primary_10_3390_cancers15123242
crossref_primary_10_3390_antiox11091686
crossref_primary_10_1016_j_biopha_2023_115517
crossref_primary_10_1016_j_ejphar_2024_176506
crossref_primary_10_3390_cells11152359
crossref_primary_10_1097_JN9_0000000000000012
crossref_primary_10_3390_ani13040657
crossref_primary_10_1016_j_jep_2024_118929
crossref_primary_10_1002_jcsm_13544
crossref_primary_10_13005_bpj_2514
crossref_primary_10_3390_cells12172167
crossref_primary_10_1007_s11011_025_01545_6
crossref_primary_10_3390_antibiotics13080757
Cites_doi 10.1016/j.trecan.2018.10.001
10.1634/theoncologist.2009-0153
10.1016/j.intimp.2014.02.007
10.1002/jcp.28992
10.1158/0008-5472.CAN-14-0135
10.1016/j.clnu.2011.07.010
10.1016/j.clnu.2012.03.005
10.1016/S0092-8674(04)00400-3
10.1074/jbc.M400674200
10.1016/0167-4781(96)00069-3
10.1038/nrdp.2017.105
10.1111/febs.12253
10.1152/physrev.00016.2008
10.3748/wjg.v12.i28.4541
10.1097/SPC.0b013e3283311d09
10.1158/1541-7786.MCR-13-0189
10.1159/000439550
10.1016/j.cell.2010.07.011
10.1358/dot.2016.52.9.2545017
10.1002/jcsm.12127
10.18632/oncotarget.19209
10.1177/0884533617722986
10.2174/1389201033489829
10.1016/j.urology.2006.09.039
10.1038/ncb1101-1014
10.1152/ajpcell.00104.2009
10.1007/s001090100234
10.1016/j.intimp.2014.02.002
10.1007/s00018-014-1689-x
10.1007/s43440-020-00179-y
10.1016/S1470-2045(10)70218-7
10.1111/cas.14170
10.1079/PNS2001110
10.1097/01.mco.0000232905.89662.60
10.1101/gad.1089403
10.1016/j.ejca.2008.02.033
10.1016/j.cmet.2007.11.001
10.1089/rej.2013.1459
10.1016/j.bbrc.2011.11.154
10.4161/cbt.12.2.15717
10.1113/jphysiol.2002.034520
10.3109/08923979109019696
10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N
10.1016/j.cmet.2012.06.011
10.14715/cmb/2019.65.7.6
10.1016/j.phymed.2013.04.020
10.1016/S0092-8674(04)00298-3
10.1016/S1097-2765(04)00211-4
10.1016/S0002-9610(02)00823-1
10.3322/caac.21442
10.1016/j.biocel.2005.04.018
10.1016/j.cellsig.2005.02.001
10.1096/fj.04-2364com
10.1016/j.cmet.2007.11.004
10.1016/j.nut.2007.12.010
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. The Author(s).
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. The Author(s).
– notice: The Author(s) 2021
DBID AAYXX
CITATION
ISR
3V.
7QP
7RV
7TS
7X7
7XB
88E
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
KB0
M0S
M1P
M2O
MBDVC
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
5PM
DOA
DOI 10.1186/s12986-021-00623-7
DatabaseName CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Nursing & Allied Health Database
Physical Education Index
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Research Library
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
Physical Education Index
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA



Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Diet & Clinical Nutrition
EISSN 1743-7075
EndPage 98
ExternalDocumentID oai_doaj_org_article_2d96e81ea85d4a71b0776218586d425c
PMC8559414
A681652984
10_1186_s12986_021_00623_7
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 81673167; 81603347
GroupedDBID ---
04C
0R~
123
29N
2WC
53G
5VS
7RV
7X7
88E
8FI
8FJ
8G5
A8Z
AAFWJ
AAHBH
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
AZQEC
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BKEYQ
BMC
BMSDO
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
DWQXO
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EIHBH
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HMCUK
HYE
IAO
ICU
IHR
ISR
ITC
KQ8
M1P
M2O
M48
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SCM
SOJ
SV3
TUS
UKHRP
WOQ
WOW
XSB
PMFND
3V.
7QP
7TS
7XB
8FK
K9.
MBDVC
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
7X8
7S9
L.6
5PM
PUEGO
ID FETCH-LOGICAL-c607t-b3f2840adcb874ce3c6f36fdd65efc35252e1f3ec6374ba9a631e9acd46b8f33
IEDL.DBID M48
ISSN 1743-7075
IngestDate Wed Aug 27 01:19:40 EDT 2025
Thu Aug 21 13:54:22 EDT 2025
Fri Jul 11 07:00:55 EDT 2025
Fri Jul 11 10:03:00 EDT 2025
Fri Jul 25 07:09:17 EDT 2025
Tue Jun 17 21:31:40 EDT 2025
Tue Jun 10 20:45:44 EDT 2025
Fri Jun 27 05:10:29 EDT 2025
Thu Apr 24 23:11:00 EDT 2025
Tue Jul 01 02:17:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c607t-b3f2840adcb874ce3c6f36fdd65efc35252e1f3ec6374ba9a631e9acd46b8f33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5215-734X
OpenAccessLink https://doaj.org/article/2d96e81ea85d4a71b0776218586d425c
PMID 34724970
PQID 2599083043
PQPubID 55142
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_2d96e81ea85d4a71b0776218586d425c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8559414
proquest_miscellaneous_2636724408
proquest_miscellaneous_2592307465
proquest_journals_2599083043
gale_infotracmisc_A681652984
gale_infotracacademiconefile_A681652984
gale_incontextgauss_ISR_A681652984
crossref_primary_10_1186_s12986_021_00623_7
crossref_citationtrail_10_1186_s12986_021_00623_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Nutrition & metabolism
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References MJ Tisdale (623_CR5) 2009; 89
M Sandri (623_CR16) 2004; 117
N Sato (623_CR30) 1981; 41
DT Wang (623_CR10) 2014; 19
F Jiang (623_CR23) 2015; 38
SF Schmidt (623_CR34) 2018; 4
A Laviano (623_CR22) 2006; 9
RS Zheng (623_CR2) 2019; 41
K Kuroda (623_CR13) 2007; 69
G Mantovani (623_CR46) 2008; 24
A Laine (623_CR8) 2013; 11
A Evangeliou (623_CR21) 2003; 4
DJ Glass (623_CR15) 2005; 37
Y Kamei (623_CR57) 2004; 279
R Tahtouh (623_CR47) 2019; 65
SW Coppack (623_CR49) 2001; 60
J Zhao (623_CR17) 2007; 6
Z Xiaolan (623_CR58) 2010; 142
KC Fearon (623_CR6) 2008; 44
S Busquets (623_CR43) 2020; 235
Y Shi (623_CR25) 2014; 19
N Yamazaki (623_CR39) 1996; 1307
RL Siegel (623_CR1) 2018; 68
S Schiaffino (623_CR53) 2013; 280
G Mantovani (623_CR51) 2010; 15
Q Yang (623_CR31) 2013; 20
S Liu (623_CR38) 2011; 12
J Szefel (623_CR40) 2012; 28
AI Graul (623_CR52) 2016; 52
K Fearon (623_CR3) 2011; 12
VE Baracos (623_CR44) 2018; 4
C Scheede-Bergdahl (623_CR12) 2012; 31
MC Seelaender (623_CR28) 1998; 44
R Sartori (623_CR56) 2009; 296
SC Bodine (623_CR20) 2001; 3
MN Goodman (623_CR32) 1991; 260
JM Argilés (623_CR33) 1999; 19
AA Maglara (623_CR27) 2003; 548
J Seoane (623_CR42) 2004; 117
K Fukami (623_CR50) 2013; 16
PE May (623_CR36) 2002; 183
M Malaguarnera (623_CR37) 2006; 12
G Mantovani (623_CR7) 2001; 79
623_CR60
Y Tanaka (623_CR29) 1990; 50
C Mammucari (623_CR55) 2007; 6
JM Argiles (623_CR9) 2009; 3
TN Stitt (623_CR54) 2004; 14
S Busquets (623_CR24) 2012; 31
N Alamdari (623_CR26) 2012; 417
C Mochamat (623_CR35) 2017; 8
KC Fearon (623_CR4) 2012; 16
CC Chou (623_CR19) 2014; 74
T Mori (623_CR48) 2019; 110
E Jirillo (623_CR45) 1991; 13
XD Peng (623_CR61) 2003; 17
J Rodriguez (623_CR59) 2014; 71
YP Li (623_CR14) 2005; 19
L Tolosa (623_CR11) 2005; 17
X Zhang (623_CR18) 2017; 8
TW Mattox (623_CR41) 2017; 32
References_xml – volume: 4
  start-page: 849
  year: 2018
  ident: 623_CR34
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2018.10.001
– volume: 15
  start-page: 200
  year: 2010
  ident: 623_CR51
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0153
– volume: 19
  start-page: 358
  year: 2014
  ident: 623_CR25
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2014.02.007
– volume: 235
  start-page: 526
  year: 2020
  ident: 623_CR43
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.28992
– volume: 74
  start-page: 4783
  year: 2014
  ident: 623_CR19
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-0135
– volume: 31
  start-page: 85
  year: 2012
  ident: 623_CR12
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2011.07.010
– volume: 31
  start-page: 889
  year: 2012
  ident: 623_CR24
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2012.03.005
– volume: 117
  start-page: 399
  year: 2004
  ident: 623_CR16
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00400-3
– volume: 279
  start-page: 41114
  year: 2004
  ident: 623_CR57
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M400674200
– volume: 1307
  start-page: 157
  year: 1996
  ident: 623_CR39
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0167-4781(96)00069-3
– volume: 4
  start-page: 17105
  year: 2018
  ident: 623_CR44
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2017.105
– volume: 280
  start-page: 4294
  year: 2013
  ident: 623_CR53
  publication-title: FEBS J
  doi: 10.1111/febs.12253
– volume: 89
  start-page: 381
  year: 2009
  ident: 623_CR5
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00016.2008
– volume: 12
  start-page: 4541
  year: 2006
  ident: 623_CR37
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v12.i28.4541
– volume: 3
  start-page: 263
  year: 2009
  ident: 623_CR9
  publication-title: Curr Opin Support Palliat Care
  doi: 10.1097/SPC.0b013e3283311d09
– volume: 11
  start-page: 967
  year: 2013
  ident: 623_CR8
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-13-0189
– volume: 38
  start-page: 511
  year: 2015
  ident: 623_CR23
  publication-title: Oncol Res Treat
  doi: 10.1159/000439550
– volume: 142
  start-page: 531
  year: 2010
  ident: 623_CR58
  publication-title: Cell
  doi: 10.1016/j.cell.2010.07.011
– volume: 52
  start-page: 519
  year: 2016
  ident: 623_CR52
  publication-title: Drugs Today (Barc)
  doi: 10.1358/dot.2016.52.9.2545017
– volume: 8
  start-page: 25
  year: 2017
  ident: 623_CR35
  publication-title: J Cachexia Sarcopenia Muscle
  doi: 10.1002/jcsm.12127
– volume: 8
  start-page: 63923
  year: 2017
  ident: 623_CR18
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19209
– volume: 32
  start-page: 599
  year: 2017
  ident: 623_CR41
  publication-title: Nutr Clin Pract
  doi: 10.1177/0884533617722986
– volume: 4
  start-page: 211
  year: 2003
  ident: 623_CR21
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201033489829
– volume: 69
  start-page: 113
  year: 2007
  ident: 623_CR13
  publication-title: Urology
  doi: 10.1016/j.urology.2006.09.039
– volume: 3
  start-page: 1014
  year: 2001
  ident: 623_CR20
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1101-1014
– volume: 296
  start-page: 1248
  year: 2009
  ident: 623_CR56
  publication-title: Am J Physiol Cell Physiol
  doi: 10.1152/ajpcell.00104.2009
– volume: 260
  start-page: E727
  year: 1991
  ident: 623_CR32
  publication-title: Am J Physiol
– volume: 79
  start-page: 406
  year: 2001
  ident: 623_CR7
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s001090100234
– volume: 41
  start-page: 19
  year: 2019
  ident: 623_CR2
  publication-title: Zhonghua Zhong Liu Za Zhi
– volume: 19
  start-page: 206
  year: 2014
  ident: 623_CR10
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2014.02.002
– volume: 71
  start-page: 4361
  year: 2014
  ident: 623_CR59
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-014-1689-x
– ident: 623_CR60
  doi: 10.1007/s43440-020-00179-y
– volume: 12
  start-page: 489
  year: 2011
  ident: 623_CR3
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70218-7
– volume: 110
  start-page: 3391
  year: 2019
  ident: 623_CR48
  publication-title: Cancer Sci
  doi: 10.1111/cas.14170
– volume: 60
  start-page: 349
  year: 2001
  ident: 623_CR49
  publication-title: Proc Nutr Soc
  doi: 10.1079/PNS2001110
– volume: 50
  start-page: 2290
  year: 1990
  ident: 623_CR29
  publication-title: Cancer Res
– volume: 9
  start-page: 442
  year: 2006
  ident: 623_CR22
  publication-title: Curr Opin Clin Nutr Metab Care
  doi: 10.1097/01.mco.0000232905.89662.60
– volume: 17
  start-page: 1352
  year: 2003
  ident: 623_CR61
  publication-title: Genes Dev
  doi: 10.1101/gad.1089403
– volume: 28
  start-page: 319
  year: 2012
  ident: 623_CR40
  publication-title: Oncol Rep
– volume: 44
  start-page: 1124
  year: 2008
  ident: 623_CR6
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.02.033
– volume: 6
  start-page: 458
  year: 2007
  ident: 623_CR55
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2007.11.001
– volume: 16
  start-page: 460
  year: 2013
  ident: 623_CR50
  publication-title: Rejuvenation Res
  doi: 10.1089/rej.2013.1459
– volume: 417
  start-page: 528
  year: 2012
  ident: 623_CR26
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.11.154
– volume: 12
  start-page: 125
  year: 2011
  ident: 623_CR38
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.12.2.15717
– volume: 548
  start-page: 837
  year: 2003
  ident: 623_CR27
  publication-title: J Physiol
  doi: 10.1113/jphysiol.2002.034520
– volume: 13
  start-page: 135
  year: 1991
  ident: 623_CR45
  publication-title: Immunopharmacol Immunotoxicol
  doi: 10.3109/08923979109019696
– volume: 44
  start-page: 185
  year: 1998
  ident: 623_CR28
  publication-title: Biochem Mol Biol Int
– volume: 19
  start-page: 223
  year: 1999
  ident: 623_CR33
  publication-title: Med Res Rev
  doi: 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N
– volume: 16
  start-page: 153
  year: 2012
  ident: 623_CR4
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2012.06.011
– volume: 41
  start-page: 2267
  year: 1981
  ident: 623_CR30
  publication-title: Cancer Res
– volume: 65
  start-page: 26
  year: 2019
  ident: 623_CR47
  publication-title: Cell Mol Biol (Noisy-le-grand)
  doi: 10.14715/cmb/2019.65.7.6
– volume: 20
  start-page: 992
  year: 2013
  ident: 623_CR31
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2013.04.020
– volume: 117
  start-page: 211
  year: 2004
  ident: 623_CR42
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00298-3
– volume: 14
  start-page: 395
  year: 2004
  ident: 623_CR54
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(04)00211-4
– volume: 183
  start-page: 471
  year: 2002
  ident: 623_CR36
  publication-title: Am J Surg
  doi: 10.1016/S0002-9610(02)00823-1
– volume: 68
  start-page: 7
  year: 2018
  ident: 623_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
– volume: 37
  start-page: 1974
  year: 2005
  ident: 623_CR15
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2005.04.018
– volume: 17
  start-page: 1333
  year: 2005
  ident: 623_CR11
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2005.02.001
– volume: 19
  start-page: 362
  year: 2005
  ident: 623_CR14
  publication-title: FASEB J
  doi: 10.1096/fj.04-2364com
– volume: 6
  start-page: 472
  year: 2007
  ident: 623_CR17
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2007.11.004
– volume: 24
  start-page: 305
  year: 2008
  ident: 623_CR46
  publication-title: Nutrition
  doi: 10.1016/j.nut.2007.12.010
SSID ssj0033490
Score 2.4098537
Snippet Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these benefits...
Background Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these...
BACKGROUND: Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms underlying these...
Abstract Background Recent studies suggest potential benefits of applying L-carnitine in the treatment of cancer cachexia, but the precise mechanisms...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 98
SubjectTerms AKT
AKT protein
Antibodies
Atrophy
blood serum
C2C12 cells
Cachexia
Cancer
Cancer cachexia
Care and treatment
Carnitine
Cell differentiation
Colon-26
Complications and side effects
Cytokines
FOXO3 protein
Gastrocnemius muscle
Health aspects
horses
inflammation
Interleukin 1
Interleukin 6
L-Carnitine
Laboratory animals
Levocarnitine
mice
Muscle atrophy
muscles
muscular atrophy
Musculoskeletal system
Myotubes
non-specific serine/threonine protein kinase
nutrition
Protein biosynthesis
Protein kinases
Proteins
Serum levels
siRNA
Skeletal muscle
Stem cells
Transcription factors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Tumors
Ubiquitination
Wasting syndrome
Western blotting
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQtCACpTIIwQFFm8SPOMflsSqIthIUaW-W7diw0m4WNVmx_ffMONlVA1K5cIoUT14z43lEM98Q8lJxI3KXF6l3IaQcm7hsZlxqRUBvzXwV-7jPzuXpN_5pLuY3Rn1hTVgPD9wzblLUlfQq90aJmpsyt4g_A35JKFmDvjm0vuDzdslUb4MZ41W2a5FRctKCV1NYbAupcwYOPy1Hbiii9f9tk_-sk7zheGb3yb0hYqTT_k0fkDu-OSRH0way5dU1fUVjDWf8OX5IkvcL38G5Ae1zSc93YPtHRH9OHf4G6SCupGbll9icD4EmhRCQrjYt3Jz-Mi2WQdN1oA7V4QoOINXtwtBhoE-khsBwMruYXzAzOTMzu6Vmu2gfksvZh8t3p-kwXiF1Miu71LIAvikztbOq5M4zJwOToa6l8MEhTGrh88C8k6zk1lRGstxXxtVcWhUYe0QOmnXjHxPKvch8zSqjrOCFDWAzXVaAuGtvg5UhIfmO2doN0OM4AWOpYwqipO4FpEFAOgpIlwl5s7_mZw-8cSv1W5ThnhJBs-MJUCU9qJL-lyol5AVqgEZYjAbrbr6bTdvqj1-_6KlUuRTwVJ6Q1wNRWMM3gBT6NgbgBCJpjSiPR5Swb914eadoerAbrYZktIKgOOMsIc_3y3gl1sI1fr2JNFi9z6W4hUYyWRY4TTwh5UiJRywarzSLHxFfXEGWyXP-5H_w9Cm5W-C2i92bx-Sgu9r4ZxDGdfYk7tjfWB9DqQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgvPCCYAMRGMggBA8oahI7jvOEykc1ENskGFLfLNuxR6U2GU0ryn_PnesWAtKeIsWXL9_5Ppy73xHyQnJd5jYvUme9TzkWcZlM29SUHq01c3Wo4z49Eyff-KdpOY0bbn1Mq9zpxKCom87iHvkI3PQa3IWMszdXP1LsGoV_V2MLjZvkFkKXYUpXNd0HXIzxOtsVykgx6sG2SUy5hQA6A7OfVgNjFDD7_9fM_2ZL_mV-JnfJneg30vGW0ffIDdcekqNxCzHz4hd9SUMmZ9giPyTJ-5lbwbmI-TmnZzvI_SOiPqcWN0NW4F1SvXBzLNEHd5OCI0gX6x5uTn_qHpOhaeepRaFYwgF4u5lpGtv6BGpwD0eT8-k506NTPTEbqjez_j65mHy4eHeSxiYLqRVZtUoN82ChMt1YIytuHbPCM-GbRpTOWwRLLVzumbOCVdzoWguWu1rbhgsjPWMPyEHbte4hodyVmWtYraUpeWE8aE6bFcD0xhlvhE9IvptsZSMAOfbBmKsQiEihtgxSwCAVGKSqhLzeX3O1hd-4lvot8nBPidDZ4US3vFRxJaqiqYWTudOybLiucoOARuDolFI0oMBsQp6jBCgEx2gx--ZSr_teffz6RY2FzEUJT-UJeRWJfAffAFzYFjPATCCe1oDyeEAJq9cOh3eCpqL26NUfWU_Is_0wXokZca3r1oEGc_i5KK-hEUxUBfYUT0g1EOLBFA1H2tn3gDIuIdbkOX90_Qs-JrcLXFChOvOYHKyWa_cE3LSVeRrW4m99PDwg
  priority: 102
  providerName: ProQuest
Title L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis
URI https://www.proquest.com/docview/2599083043
https://www.proquest.com/docview/2592307465
https://www.proquest.com/docview/2636724408
https://pubmed.ncbi.nlm.nih.gov/PMC8559414
https://doaj.org/article/2d96e81ea85d4a71b0776218586d425c
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELf28cILgg1ExqgMQvCAQpPYcZwHhDpYNRDt0Nikvlm2Y49KbQJNK7r_nrObVASmiadI8cVRfHe-O-fudwi95FSmsY6T0GhrQ-qKuFQkdahS66w1Mbmv4x6N2dkV_TxJJzuobXfULGB9a2jn-kldLWZv1z9v3oPCv_MKz1m_BpvFXSotBMYRmPMw20X7YJkyp6gjuv2rQAjNmwJJoAFb2RbR3DpHx1B5PP9_d-2_Myn_ME3DB-h-41PiwUYIHqIdUx6gw0EJ8fT8Br_CPsvTH58foODj1CzhXoMHOsPjFo7_EIkvoXYHJUvwPLGcm5kr3wdXFIOTiOerGibHv2TtEqVxZbF2ArOAC_B9PZW4afnjqcF17A_PJ-dE9kdyqNZYrqf1I3Q5PL38cBY2DRhCzaJsGSpiwXpFstCKZ1QbopklzBYFS43VDkg1MbElRjOSUSVzyUhscqkLyhS3hDxGe2VVmicIU5NGpiC55CqlibKwq-ooAYEojLKK2QDF7WIL3YCTux4ZM-GDFM7EhkECGCQ8g0QWoDfbZ35soDnupD5xPNxSOlhtf6NaXItGS0VS5Mzw2EieFlRmsXJgR-AEpZwVsLnpAL1wEiAccEbpMnOu5aquxadvF2LAeMxSeCsN0OuGyFbwDcCFTaEDrITD2upQHncoQbN1d7gVNNEqhoBwNQe3OaIkQM-3w-5Jly1XmmrlaVx-P2XpHTSMsCxx_cYDlHWEuLNE3ZFy-t0jkHOIQ2lMj_5j9qfoXuK0ypdvHqO95WJlnoEft1Q9tJtNsh7aPzkdf73o-dOQnlfY3_UZRqY
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELem7gFeEGwgMgYYxMcDiprEjpM8ILSxVS3bOjSKtDfLduxRqU3H0mrdH8X_yF2aDAJS3_ZUKb6kzd35Pty73xHyJuUqDk0Y-dY453Ns4tKBMr6OHXprZrOqj_tkKPrf-Zfz-HyD_Gp6YbCssrGJlaHOZwbPyLsQpmcQLgScfbr86ePUKPx3tRmhsVKLI3tzDSlb-XFwAPJ9G0W9w9Hnvl9PFfCNCJK5r5kDkxyo3Og04cYyIxwTLs9FbJ1BdNDIho5ZI1jCtcqUYKHNlMm50KnD80-w-JucQSbTIZv7h8OvZ43pZ4xnQdOZk4puCc40xRpfyNgDiDP8pOX9qiEB_7uCf8sz__J3vYfkQR2o0r2VZj0iG7bYItt7BSTp0xv6jlalo9WZ_BbxDsZ2DtdqkNEJHTYY_9tEAkfw9GUO4SxVUztBTACIbylEnnS6KOHh9FqVWH1NZ44a1MIr-ABlWo4VrecIVdQQj3Z7p-enTHVPVE8vqVqOy8dkdBf8f0I6xaywTwnlNg5szjKV6phH2oGpNkEEWpZb7bRwHgkbZktTI57j4I2JrDKfVMiVgCQISFYCkolHPtzec7nC-1hLvY8yvKVErO7qwuzqQtZbX0Z5JmwaWpXGOVdJqBFBCSKrOBU5WEzjkdeoARLROAos97lQi7KUg29nck-koYjhW7lH3tdEbgbvAFJYdU8AJxDAq0W526IEc2Hay42iydpclfLP5vLIq9tlvBNL8Ao7W1Q02DTARbyGRjCRRDjE3CNJS4lbLGqvFOMfFax5CsktD_nO-h_4ktzrj06O5fFgePSM3I9wc1WtobukM79a2OcQI871i3pnUiLv2Bb8BmCRe6c
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=L-carnitine+ameliorates+the+muscle+wasting+of+cancer+cachexia+through+the+AKT%2FFOXO3a%2FMaFbx+axis&rft.jtitle=Nutrition+%26+metabolism&rft.au=Wu%2C+Changpeng&rft.au=Zhu%2C+Mingxing&rft.au=Lu%2C+Zongliang&rft.au=Zhang%2C+Yaowen&rft.date=2021-11-01&rft.issn=1743-7075&rft.eissn=1743-7075&rft.volume=18&rft.issue=1+p.98-98&rft.spage=98&rft.epage=98&rft_id=info:doi/10.1186%2Fs12986-021-00623-7&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-7075&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-7075&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-7075&client=summon